Pharmacokinetics of recombinant human thrombopoietin (rhTPO) after intravenous administration in cancer patients.

被引：0
|
作者：
Bloedow, D
VadhanRaj, S
Paton, V
Johnston, T
Yang, T
Senn, T
Ashby, M
Sims, P
机构：
[1] GENENTECH INC,S SAN FRANCISCO,CA 94080
[2] MD ANDERSON CANC CTR,HOUSTON,TX 77030
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1392 / 1392
页数：1
相关论文
共 50 条
  • [31] Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecologic malignancy.
    VadhanRaj, S
    Verschraegen, C
    McGarry, L
    BuesoRamos, C
    Kudelka, A
    Freedman, R
    Edwards, C
    Bevers, M
    Levenback, C
    Gershenson, D
    Jones, D
    Yang, T
    Bast, RC
    Kavanagh, J
    BLOOD, 1997, 90 (10) : 2581 - 2581
  • [32] ERYTHROMYCIN - PHARMACOKINETICS AFTER INTRAVENOUS ADMINISTRATION
    MATHER, LE
    AUSTIN, KL
    PHILPOT, CR
    MCDONALD, PJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1978, 23 (01) : 120 - 121
  • [33] Schedule effect of recombinant human thrombopoietin (rhTPO) in attenuating thrombocytopenia in patients receiving dose intensive chemotherapy with adriamycin (A) and ifosfamide (I).
    Vadhan-Raj, S
    Patel, S
    Broxmeyer, HE
    Bueso-Ramos, CE
    Hangoc, G
    Papadopolous, NE
    Burgess, MA
    Plager, C
    Brown, CA
    Hays, CF
    Benjamin, RS
    BLOOD, 2000, 96 (11) : 455A - 455A
  • [34] The Combination of Intravenous Immunoglobulin (IVIG) and Low Does Recombinant Human Thrombopoietin (rhTPO) for the Management of Corticosteroid/IVIG Monotherapy-Resistant Immune Thrombocytopenia in Pregnancy
    He, Yun
    Fu, Haixia
    Zhu, Xiaolu
    Huang, Qiusha
    Chen, Qi
    Wu, Jin
    Chen, Yuxiu
    Zhao, Peng
    Liu, Kai-Yan
    Zhang, Xiaohui
    BLOOD, 2023, 142
  • [35] Efficacy and Safety of Recombinant Human Thrombopoietin (rhTPO) on Coagulation Function and Inflammatory Factors in the Treatment of Patients with Sepsis-Related Thrombocytopenia
    Wang, Huijuan
    Chen, Dong
    He, Ming
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2025, 31
  • [36] Pharmacokinetics and peripheral platelet counts after a single dose of recombinant human thrombopoietin in rhesus monkeys
    Song, HF
    Liu, XW
    Tang, ZM
    ACTA PHARMACOLOGICA SINICA, 1999, 20 (03) : 244 - 248
  • [37] Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys
    McCarthy, K
    Stewart, P
    Sigman, J
    Read, M
    Keith, JC
    Brinkhous, KM
    Nichols, TC
    Schaub, RG
    THROMBOSIS AND HAEMOSTASIS, 2002, 87 (05) : 824 - 830
  • [38] PHARMACOKINETICS AND ABSORPTION OF FOSCARNET AFTER INTRAVENOUS AND ORAL-ADMINISTRATION TO PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS
    SJOVALL, J
    KARLSSON, A
    OGENSTAD, S
    SANDSTROM, E
    SAARIMAKI, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (01) : 65 - 73
  • [39] REPEATED-DOSE PHARMACOKINETICS OF INTRAVENOUS ITRACONAZOLE IN PEDIATRIC CANCER PATIENTS.
    Shin, D.
    Kim, H.
    Kang, H.
    Yoon, S. H.
    Cho, J. Y.
    Shin, S. G.
    Yu, K. S.
    Jang, I. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S91 - S92
  • [40] Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer
    Zhang, Steven
    Zannikos, Peter
    Awada, Ahmad
    Piccart-Gebhart, Martine
    Dirix, Luc Y.
    Fumoleau, Pierre
    Verhaeghe, Tom
    Francois, Marc
    De Porre, Peter
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (10): : 1116 - 1127
12345